This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Moderna (MRNA) Q3 Earnings Miss, COVID-19 Vaccine Brings $5B
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine sales miss expectations. The company delivers 208 million doses of its COVID-19 vaccine during the third quarter. Stock declines in pre-market.
Sarepta (SRPT) Q3 Earnings Beat, 2021 Sales View Raised
by Zacks Equity Research
Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the third quarter. The company also raises revenues guidance for the year. Stock up in after-market trading.
Company News for Nov 4, 2021
by Zacks Equity Research
Companies In The News Are: VRTX, ATH, DISCA, MAR.
CRISPR Therapeutics (CRSP) Q3 Earnings Beat, Revenues Lag
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reports narrower-than-expected Q3 loss. Yet, revenues miss estimates for the third quarter of 2021.
Amarin (AMRN) Q3 Earnings Top, Vascepa Sales Decline Y/Y
by Zacks Equity Research
Amarin's (AMRN) reports lower sales volume for its drug, Vascepa, in the United States during the third quarter. The company's stock falls in pre-market trading.
Vertex (VRTX) Beats on Q3 Earnings & Sales, Raises '21 View
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) earnings and sales beat estimates for the third quarter of 2021. The company raises its product revenue guidance for the year.
Halozyme (HALO) Beats on Q3 Earnings, Tweaks 2021 Guidance
by Zacks Equity Research
Halozyme (HALO) third-quarter earnings and sales beat estimates. The company raises the lower end of its previously guided range for earnings and revenues for 2021. Stock up.
Vertex Pharmaceuticals (VRTX) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of 14.10% and 7.21%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Cassava Sciences (SAVA) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Investors will watch for updates on its lead candidate, sumifilam, for Alzheimer's disease in Cassava's (SAVA) Q3 earnings call.
Will Eylea, Dupixent, REGEN COV Aid Regeneron (REGN) Q3 Earnings?
by Zacks Equity Research
Regeneron's third-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent and incremental contribution from its antibody cocktail.
CVS Health (CVS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
CVS Health's (CVS) consumer-centric digital approach to administering vaccines across the nation is expected to have strongly contributed to its Q3 performance.
Amgen (AMGN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Volume growth of Amgen's (AMGN) key drugs like Prolia, Kyprolis, Repatha and others and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Zimmer Biomet (ZBH) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Strong surgeon registrations of the Signature One surgical planning system for shoulder procedures are likely to have driven Zimmer Biomet's (ZBH) growth in Q3.
4 Big Drug, Biotech Stocks Set to Beat Q3 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.
Repligen (RGEN) Q3 Earnings and Sales Beat, 2021 View Up
by Zacks Equity Research
Repligen's (RGEN) third-quarter earnings and revenues beat estimates. The company raises its guidance for 2021. Resultantly, the stock rises.
Why Earnings Season Could Be Great for Vertex Pharmaceuticals (VRTX)
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
VRTX vs. PRTA: Which Stock Is the Better Value Option?
by Zacks Equity Research
VRTX vs. PRTA: Which Stock Is the Better Value Option?
Charles River (CRL) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Robust demand for research models and the Vigene Biosciences buyout are likely to have contributed to growth for Charles River (CRL).
STERIS (STE) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Strong gains from the recent Cantel Medical buyout as well as the addition of a new Dental arm are expected to have contributed STERIS' (STE) Q2 performance.
Sanofi (SNY) Q3 Earnings Beat, Sales Miss, 2021 EPS View Up
by Zacks Equity Research
Sanofi (SNY) beats third-quarter estimates for earnings but misses the same for sales. It raises earnings growth guidance range for the year.
Merck (MRK) Beats on Q3 Earnings & Sales, Ups 2021 View
by Zacks Equity Research
Merck (MRK) beats Q3 estimates for earnings and sales. It raises financial guidance for 2021. The stock moves up in the pre-market trading session.
Recovery in Drugs Sales to Aid AbbVie's (ABBV) Q3 Earnings
by Zacks Equity Research
AbbVie (ABBV) is expected to have witnessed a recovery in demand trends of new drugs amid the receding impact of the pandemic. However, sales of physician-administered drugs are likely to have been hurt by the residual impact.
Biotech Stock Roundup: BMY's Q3 Earnings Beat, MRNA's Vaccine Updates & More
by Zacks Equity Research
Earnings and other updates from bigwigs like Bristol Myers (BMY) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.
Vertex (VRTX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex Pharmaceuticals' (VRTX) third-quarter earnings call, investors are most likely to focus on the sales performance of its triple combo CF drug Trikafta/Kaftrio and pipeline progress.
IDEXX (IDXX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Strong organic recurring revenue growth in CAG diagnostics business and the recent ezyVet buyout are likely to have contributed to growth for IDEXX (IDXX).